Introduction {#s1}
============

Dementias including Alzheimer\'s disease, vascular dementia, Parkinson\'s disease and Lewy body disease, have a significant impact on global health due to the increasing number of older individuals suffering from this disease (Prince et al., [@B45]). Developing effective methods for preventing, delaying or treating dementia are pressing priorities. The highest risk factor for dementia is chronological age, with an annual incidence of Alzheimer\'s disease doubling every 5 years past the age of 65 years (Bermejo-Pareja et al., [@B2]). Dementia subtypes share several pathological processes including abnormal accumulation of misfolded proteins such as; amyloid beta (Aβ) and tau in Alzheimer\'s disease, and alpha-synuclein in Parkinson\'s disease and Lewy Body disease (Ganguly et al., [@B11]). Loss of proteostasis is an important feature during the aging process (López-Otín et al., [@B28]), suggesting the age-related decline in the ability to refold or degrade damaged proteins may contribute to the exponential rise in dementia incidence observed with increasing age (Yerbury et al., [@B64]).

Several drugs already approved for their use in humans are known to enhance proteostasis including; lithium, mTOR inhibitors (sirolimus/rapamycin, everolimus), and tyrosine kinase inhibitors (nilotinib). The concept of modifying aging with a repurposed drug to prevent multiple diseases of aging will soon be tested in the Targeting Aging with Metformin (TAME) trial. TAME will examine Metformin\'s ability to prevent diseases of aging in non-diabetic elderly, including cognitive impairment (Barzilai et al., [@B1]), via targeting the deregulated nutrient sensing associated with aging. Applying a similar strategy to target the loss of proteostasis could be effective in preventing and/or treating age-related dementia.

This systematic review will examine the evidence for targeting proteostasis with repurposed drugs as an intervention for age-related dementia and cognitive decline.

Methods {#s2}
=======

Protocol registration and search strategy
-----------------------------------------

The protocol of this systematic review was registered at PROSPERO International prospective register of systematic reviews (Reg \#: CRD42018091645). PubMed, Web of Science and Embase databases were used for this search from inception until 4th July 2017. The complete search strategy is presented in Supplementary Data [1](#SM1){ref-type="supplementary-material"}. Key search terms included; "vascular dementia," "Alzheimer^\*^ disease" "Lewy Body Disease," "Parkinson^\*^ disease," "cognitive aging," "autophag^\*^," "lysosom^\*^," "proteasome endopeptidase complex," "molecular chaperone^\*^," "unfolded protein response," "insulin^\*^," "mTOR," "GSK-3," "akt," "PI3K," "AMPK," "sirtuin^\*^," "sirolimus," "everolimus," "temsirolimus," "rapamycin," "metformin," "DPP-4," "GLP-1," "nicotinamide," "NAD," "spermidine," "imatinib," "nilotinib," "dasatinib," "bosutinib," "ponatinib," "bafetinib," "lithium," "heat-shock protein," "calori^\*^ restriction," "carbohydrate restricted diet," "protein restricted diet". In addition to the database search a "snowballing" method was used to identify relevant articles out of the reference section and PubMed citations of each included article. After duplicates were removed studies were then screened for inclusion using Covidence systematic review software *(Veritas Health Innovation, Melbourne, Australia)*.

Eligibility criteria
--------------------

### Type of studies

The search was designed to retrieve all published research studies that investigated the effect of modifying protein homeostasis or deregulated nutrient sensing (DNS) on cognitive function in age-related neurodegenerative disease and normal aging populations. To be included in this review the study had to report on one or more neuropsychological tests measuring change in cognitive function. To meet the criteria of modifying protein homeostasis or deregulated nutrient sensing, the intervention had to be previously demonstrated to modulate these pathways, or data had to be provided proving the intervention\'s effect on these pathways. Animal *in vivo* models and human trials were included in this review. The following Dementia populations/models were specifically targeted; Alzheimer\'s disease, Vascular Dementia, Parkinson\'s disease and Lewy Body Disease. In addition, normal aging populations, defined as a population not suffering from dementia and over the age of 18 years for human studies, as well as populations likely to have a higher pace of aging such as animal models with diabetes or obesity were included. Randomized controlled trials (RCTs) and non-randomized studies comparing outcomes to either retrospective or prospective controls met the inclusion criteria. Studies were excluded if they met the following criteria; observational studies, exercise as the sole intervention, *in vitro* data only, conference abstracts, reviews, editorials, letters to the editor, case reports with ≤5 population size, or published in a language other than English.

### Outcome

In animals (using mice as an example), cognitive tests would include spatial memory tests (Morris water maze \[MWM\], radial arm water maze \[RAWM\], Barnes maze), associative learning tasks (passive avoidance, fear conditioning), alternation tasks (Y-Maze/T-Maze), recognition memory tasks (Novel Object Recognition), attentional tasks (3 and 5 choice serial reaction time), set-shifting tasks, and reversal learning tasks. In human studies examples of neuropsychological measures would be cognitive testing batteries commonly used in clinical or research settings to examine cognitive function, such as the Mini-Mental State Examination (MMSE), Rowland Universal Dementia Assessment Scale (RUDAS), Neuropsychiatry Unit Cognitive Assessment Tool (NUCOG), Montreal Cognitive Assessment (MOCA), Clinical Dementia Rating Scale Sum of Boxes (CDR-SoB), Addenbrooke\'s Cognitive Examination (ACE) or Alzheimer\'s Disease Assessment Scale-cognitive subscale (ADAS-Cog).

Study selection
---------------

Two review authors (DH and CT) independently screened the titles and abstracts and subsequently the full text articles of potentially relevant studies against the inclusion and exclusion criteria. A third reviewer (ABM) resolved any disagreements between the authors.

Included studies were separated into the following four groups for data extraction (1) proteostasis--repurposed drug, (2) proteostasis--novel intervention (defined as a novel molecule, botanical extract, or dietary manipulation), (3) DNS--repurposed drug and (4) DNS--novel intervention. Where an intervention is thought to modify both pathways (for example the mTOR inhibitor, rapamycin) it was included in the loss of proteostasis group. The current paper presents the results of the 1st group: proteostasis---repurposed drugs.

Data extraction and quality assessment
--------------------------------------

The following variables were extracted independently by two reviewers (DH and CT): author, year of publication, study design, species, animal model/population (dementia subtype or normal aging), sample size, age, sex, baseline cognition/stage of disease, duration of study, cognitive outcome, drug, comparator, setting, hallmark(s) of aging targeted by the intervention, and journal citation. For binary outcomes the number of events and total number in group, percentage of events or ratios with confidence intervals; for continuous outcomes, mean or median, standard deviation, standard error, confidence intervals or interquartile range, and number of participants; other reported results such as mean difference and *p*-values of measures of cognitive function.

Risk of bias was assessed by two reviewers (DH, CT) using the Cochrane Risk of Bias tool (Higgins et al., [@B15]) for human studies and SYRCLE\'s risk of bias tool for animal studies. The SYRCLE RoB tool is an adaptation of the Cochrane tool for use in systematic reviews of laboratory animal studies (Hooijmans et al., [@B17]).

Registered human trials
-----------------------

To establish the progress of repurposed drugs into human studies which have not yet been completed, clinicaltrials.gov was searched for registered studies of the drugs identified in our search in Alzheimer\'s disease, Parkinson\'s disease, Lewy Body Disease and Vascular Dementia.

Results {#s3}
=======

Study selection and characteristics
-----------------------------------

The literature search and selection process for this review is illustrated in Figure [1](#F1){ref-type="fig"}. After exclusion of duplicates the remaining 1,687 studies were screened for Title and Abstracts of which 413 underwent full text screening. An additional 22 studies were identified via snowballing. Overall, 47 articles specifically investigating a proteostasis intervention on Dementia and cognitive aging were included in this review. The repurposed drugs used in these intervention studies are outlined in Tables [1](#T1){ref-type="table"}, [2](#T2){ref-type="table"} and Supplementary Table [1](#SM1){ref-type="supplementary-material"}. The following drugs were found testing the modification of cognition in animal and human studies; lithium (*n* = 10 animal, *n* = 6 human), rapamycin (*n* = 12 animal, *n* = 1 human), rifampicin (*n* = 1 animal, *n* = 1 human), tyrosine kinase inhibitors (bosutinib *n* = 1 animal, nilotinib *n* = 1 human), Macrophage Colony Stimulating Factor (M-CSF; *n* = 1 animal), Granulocyte Macrophage Colony Stimulating Factor (GM-CSF; n = 1 animal), methylene blue (*n* = 4, animal), geranylgeranylacetone (GGA; *n* = 2 animal), dantrolene (*n* = 3 animal), minocycline (*n* = 2 animal) and phenylbutyric acid (*n* = 1 animal). Doxycycline was tested in a single human trial only. Of these drugs only lithium, rapamycin, rifampicin, and the tyrosine kinase inhibitors have been tested in both animal and human studies (Figure [2](#F2){ref-type="fig"}).

![Study selection process.](fphys-09-01520-g0001){#F1}

###### 

Characteristics of animal studies testing the effect of lithium (a), rapamycin (b), rifampicin (c), bosutinib (d) on cognition.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
      **Author, Year**               **Species**            **Model**                                                   **Sample size (*****n*****)**   **Age**                    **Sex (%F)**   **Baseline cognition**   **Duration**   **Dose**   
  --- ------------------------------ ---------------------- ----------------------------------------------------------- ------------------------------- -------------------------- -------------- ------------------------ -------------- ---------- ------------------------------------------------------------------
  a   Caccamo et al., [@B6]          Mouse                  AD (3xTg)                                                   Wt: 10Tg: 10                    Wt: 10Tg: 10               15m            NR                       Est            4w         300μl of 0.6mol/L/d IP

  a   Rockenstein et al., [@B46]     Mouse                  AD (Tg hAPP)                                                WT: 6Tg: 6                      WT: 6Tg: 6                 3m             NR                       Est            3m         20mg/kg/d IP

  a   Fiorentini et al., [@B9]       Mouse                  AD (TgCRND8)                                                Ear: 8Est: 8                    Ear: 8Est: 8               2m6m           Mix                      EarEst         5w         0.223mEq/L IP

  a   Toledo and Inestrosa, [@B55]   Mouse                  AD (Tg APP- PS1)                                            3-≥6                            3-≥6                       9m             NR                       Est            12w        0.2--1.5 meq/L

  a   Sy et al., [@B53]              Mouse                  AD (3xTg)                                                   Na = 6LPS = 6                   Na = 6LPS = 6              11--13m        67                       Est            6w         6--10mg/d food

  a   Nunes et al., [@B40]           Mouse                  AD (Cg- Tg(PDGFB- APPSwInd) 20Lms/2J)                       Pre: 8Est: 7WT: NR.             WT: 12TG: 7                2m10m          0                        PreEst         16m8m      0.25mg/kg/d (H2O)

  a   Nocjar et al., [@B39]          Rat                    Aging (Sprague-Dawley)                                      16                              14                         2m             0                        Pre            80d        0.72mEq/l food

  a   Wilson et al., [@B62]          Rat                    AD (Tg McGill- R-Thy1-APP)                                  WT: ≥5Tg:≥5                     WT: ≥5Tg:≥5                3m             Mix                      Ear            2m         Li 40μg/kg/d PR

  a   Nery et al., [@B37]            Zebrafish              AD (ICV Aβ)                                                 No inj: 10Veh: 10 AB: 10        No inj: 10Veh: 10 AB: 10   5d             Mix                      Pre            5d         100μm (H2O)

  a   McBride et al., [@B32]         Drosophila             AD (Tg psn\[B3\]/+, psn\[I2\]/+) PD (Tg 30Y-GAL4:UAS-Syn)   Pre: 72                         Pre: 70                    30d            0                        Pre            25d        5mM Li food

                                                                                                                        Est: 74                         Est: 75                    45d                                     Est            15d        

                                                                                                                        PD: 39                          PD: NR                                                                                       

                                                                                                                                                                                                                                                     

  b   Spilman et al., [@B50]         Mouse                  AD (Tg hAPP) Aging (C57BL/6J)                               12 10                           12 10                      7m             0                        Ear YA         3m         14mg/kg food

  b   Majumder et al., [@B31]        Mouse                  AD (3xTg) Aging (C57BL6/ 129svj)                            4040                            20 20                      18m            NR                       PreEst         16m3m      14mg/kg food

  b   Halloran et al., [@B13]        Mouse                  Aging (C57BL/6J)                                            9--14                           9--14                      12m25m         Mix                      MAOA           40w        14mg/kg food

  b   Majumder et al., [@B30]        Mouse                  Aging (C57BL/6/ 129svj)                                     2020                            20                         18m            NR                       YAMA           16m3m      14mg/kg food

  b   Lin et al., [@B26]             Mouse                  AD (Tg hAPP)                                                Tg: 10                          Tg: 10                     7m             0                        Est            16w        14mg/kg food

                                                                                                                        WT: 18                          WT: 17                                                             YA                        

  b   Neff et al., [@B35]            Mouse                  Aging (C57BL/6Jrj)                                          YA: 20                          YA: 20                     4m             0                        YA             12m        14mg/kg food

                                                                                                                        MA: 21                          MA: 21                     13m                                     MA                        

                                                                                                                        OA: 27                          OA: 27                     20--22m                                 OA                        

  b   Wang et al., [@B58]            Mouse                  Aging (C57BL/6J, stz diabetic)                              9                               9                          3m             0                        Est            45d        2.24mg/kg/d PO

  b   Lin et al., [@B25]             Mouse                  AD (APOE4 Tg)                                               15                              15                         7m             100                      Pre            6m         14mg/kg food

  b   Jahrling et al., [@B21]        Mouse                  VD (LDL-R--/-- HFD)                                         10                              10                         12m            0                        Est            16w        14mg/kg food

  b   Zhang et al., [@B65]           Mouse                  AD (3xTg)                                                   10                              10                         7m             50                       Ear            2m         1mg/kg/d PO

  b   Wang et al., [@B59]            Rat - Sprague Dawley   AD (ICV Aβ)                                                 18                              20                         6m             0                        Pre            2w         500 microg ICV/2w

  b   Zhu et al., [@B66]             Rat                    AD (scop Wistar)                                            10                              10                         NR             0                        Pre            14d        3.5mg/kg/d IP

  c   Umeda et al., [@B56]           Mouse                  AD (Tg APPOSK), (tau609) Aging (WT)                         APPOSK\                         APPOSK\                    APP\           0                        Est            1m         \[5pt\]0.5mg/d (APP12m, APP18m, tau8m) 1mg/d PO (APP18m, tau15m)
                                                                                                                        12m\                            12m: 9\                    11m\                                                              
                                                                                                                        0.5mg: 9\                       18m: 10\                   17m\                                                              
                                                                                                                        18m\                            WT\                        \                                                                 
                                                                                                                        0.5mg: 10\                      8m: 10\                    Tau\                                                              
                                                                                                                        1mg: 10\                        12m: 10\                   7m\                                                               
                                                                                                                        Tau609\                         15m: 11\                   14m                                                               
                                                                                                                        8m\                             18m: 16\                                                                                     
                                                                                                                        0.5mg: 8\                       Tau609\                                                                                      
                                                                                                                        15m\                            8m: 9\                                                                                       
                                                                                                                        1mg: 7                          15m: 7                                                                                       

  d   Lonskaya et al., [@B27]        Mouse                  AD (ICV lentiviral Aβ42, C57BL6) AD (Tg APP model)          Aβ42: 12\                       Aβ42: 12\                  11m            NR                       Est            3w         5mg/kg/d IP
                                                                                                                        Tg: 12                          Tg: 12                                                                                       
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*3xTg, triple transgenic; Aβ, amyloid beta; AD, Alzheimer\'s dementia; Ctrl, control; d, days; Ear, early disease; Est, established; F, female; hAPP, human amyloid precursor J20; HFD, High fat diet; ICV, intracerebroventricular; Inj, injection; IP, intra-peritoneal; LDL-R--/--, low density lipoprotein receptor knockout; Li, lithium; LPS, lipopolysaccharide; m, months; MA, middle age; NR, not reported; OA, Old Age; PD, Parkinson\'s disease dementia; PO, per oral; PR, per rectum; Pre, presymptomatic; Rapa, rapamycin; Scop, scopolamine; stz, streptozocin induced; Tg, transgenic; VD, vascular dementia; w, weeks; WT, wild type; YA, young adult*.

###### 

Characteristics of human studies testing the effect of lithium (a), rapamycin (b), rifampicin & doxycycline (c) and nilotinib (d) on cognition.

      **Author, year**           **Design**        **Condition**   **Sample size (n)**                **Age (yrs)**   **Female (%)**                                                           **Baseline cognition**   **Duration**   **Dose**            
  --- -------------------------- ----------------- --------------- ---------------------------------- --------------- ------------------------------------------------------------------------ ------------------------ -------------- ------------- ----- ----------------------------------------------------------
  a   Pomara et al., [@B44]      OL(pre-post)      AD              7                                  NA              "Geriatric"                                                                                       NR             NR            6w    0.53 mmol/L (mean at 6w)
  a   Macdonald et al., [@B29]   OL (match ctrl)   AD              22                                 44              80.9 ± 7.9                                                               81.2                     59             MMSE 12--24   12m   0.3--0.8 mmol/L
  a   Hampel et al., [@B14]      RCT               AD              33                                 38              68.2 ± 7.2                                                               68.9 ± 8.3               52             MMSE 21--26   10w   0.5--0.8 mmol/l
  a   Leyhe et al., [@B24]       RCT               AD              13                                 14              71.0 ± 9.0                                                               69.4 ± 8.5               59             MMSE 21--26   10w   0.5--0.8 mmol/L
                                                                                                                                                                                                                                                           
  a   Forlenza et al., [@B10]    RCT               AD-MCI          23                                 22              70.9 ± 5.3                                                               74.2 ± 6.5               NR             MCI           12m   0.25--0.5 mmol/L
                                                                                                                                                                                                                                                           
  a   Nunes et al., [@B41]       RCT               AD              58                                 55              77.0 ± 0.1                                                               78.0 ± 0.76              66             MMSE 12--24   15m   300 μg/d
                                                                                                                                                                                                                                                           
  b   Kraig et al., [@B23]       RCT               Aging           11                                 14              80.4 ± 8.6                                                               80.6 ± 7.9               28             OA            8w    1mg/d PO
                                                                                                                                                                                                                                                           
  c   Molloy et al., [@B34]      RCT               AD              Rif: 101 Dox: 102 Rif + dox: 101   102             Rif:78.6 (73.5--82.3) Dox: 78.7 (74.1--83.6) Rif+dox:79.2 (74.4--83.5)   78.6 (72.4--83)          50             MMSE 20--25   12m   Rif: 300mg/d Dox: 100mg BD Rif + dox: 300mg/d + 100mg BD
  d   Pagan et al., [@B42]       OL (pre-post)     PD              12                                 NA              71.8 (49--89)                                                            NA                       25             MoCA 9--28    6m    Nilo 150mg or 300mg/d

*OL, open label; RCT, randomized controlled trial; AD, Alzheimer\'s Disease, PD, Parkinson\'s disease; LBD, Lewy Body Disease; MMSE, Mini mental state exam; MoCA, Montreal Cognitive Assessment; NR, not reported; SD, standard deviation; MCI, Mild Cognitive Impairment; Li, lithium; Ctrl, control; NA, Not applicable; D, days; W, weeks; M, months; Rx, treatment; Rif, rifampicin; Dox, doxycycline; PL, placebo; Nilo, nilotinib; Age, refers to age at baseline of study*.

![Proteostasis Drugs and Cognitive Outcomes: From Animals to Humans. A schematic overview of trials investigating the influence of proteostasis drugs on cognitive outcomes. One bar is equal to one trial, green indicates a positive result for at least one cognitive outcome and black is indicative of no positive outcomes. X represents a registered trial. Trials are arranged in chronological order.](fphys-09-01520-g0002){#F2}

Lithium and cognitive aging
---------------------------

Lithium was the most investigated proteostasis modulator for cognitive aging. Overall 16 studies (6 humans, 6 mice, 2 rats, 1 drosophila, and 1 zebrafish) investigating the influence of lithium on cognitive aging were found. The majority of these studies utilized an Alzheimer\'s animal model or were conducted in an Alzheimer\'s population (Tables [1](#T1){ref-type="table"}, [2](#T2){ref-type="table"}). The findings of these studies were largely positive with all animal studies, bar one (Caccamo et al., [@B6]), reporting the use of lithium as having a statistically significant beneficial impact on at least one cognitive outcome irrespective of treatment duration (Table [3](#T3){ref-type="table"}). The findings of the animal studies are consistent with the lithium human studies (Table [4](#T4){ref-type="table"}), with three randomized controlled studies showing a statistically significant benefit of the use on lithium on either the ADAS-Cog or MMSE (Leyhe et al., [@B24]; Forlenza et al., [@B10]; Nunes et al., [@B41]). The other three studies, two of which were open-label (Pomara et al., [@B44]; Macdonald et al., [@B29]) and one RCT (Hampel et al., [@B14]), did not show cognitive benefits after treatment with lithium.

###### 

Results of animal studies testing the effect of lithium (a), rapamycin (b), rifampicin (c) and bosutinib (d) on cognition.

      **Author, year**               **Cognitive tests**                               **Outcomes**                                                              **Significance**
  --- ------------------------------ ------------------------------------------------- ------------------------------------------------------------------------- ------------------
  a   Caccamo et al., [@B6]          T-maze (Alternation %)                            Wt Li−66.67 (8.7), ctrl−72.15 (2.4)                                       ±
                                                                                       Tg Li−55.71 (5.6), ctrl−55.21 (5.8)                                       ±
  a   Nocjar et al., [@B39]          **Hole-board spatial discrimination task:**                                                                                 
                                     Search time (s) session 6                         Li−6 (1), Ctrl−20 (3)                                                     \+
                                     Repeat visits (\# lower = better)                 Li−0.6 (0.1), Ctrl−1.5 (0.4)                                              \+
                                     Number of errors (\# lower = better)              Li−1.6 (0.2), Ctrl−1.9 (0.2)                                              ±
                                     **T-maze delayed alternation task:**                                                                                        
                                     Sessions to reach criterion (\#)                  Li−13.5 (1), Ctrl−20 (1.5)                                                \+
                                     **Social conditioned place preference:**                                                                                    
                                     Percent correct (%)                               1min Li−75 (2.5), Ctrl−72.5 (5)                                           ±
                                                                                       3min Li−70 (3), Ctrl−58 (4)                                               \+
                                                                                       5min Li−65 (2.5), Ctrl−60 (2.5)                                           ±
                                     Run time (min)                                    1min Li−3.7 (1), Ctrl−1.9 (0.2)                                           NR
                                                                                       3min Li−2.7 (0.5), Ctrl−2.8 (0.5)                                         ±
                                                                                       5min Li−2.9 (0.5), Ctrl−3.2 (0.5)                                         ±
                                     Preference for social chamber (s):                Li−280 (100), Ctrl−175 (100)                                              \+
  a   Rockenstein et al., [@B46]     **Morris water maze:**                                                                                                      
                                     Meters to reach platform day 7                    Tg Li−3 (0.5), ctrl−11.5 (3)                                              \+
                                                                                       Wt Li−3.25 (0.5), ctrl−3 (0.5)                                            
                                     Platform crosses (\#)                             Tg Li−7 (1.5), ctrl−6 (1)                                                 ±
                                                                                       Wt Li−6 (2), ctrl−7 (1)                                                   
                                     Time in target quadrant (s)                       Tg Li−16 (3), ctrl−18 (2)                                                 ±
                                                                                       Wt Li−15 (3), ctrl−16 (3)                                                 
  a   Fiorentini et al., [@B9]       **Morris water maze:**                            Early stage disease (3 months)                                            
                                     Escape latency day 4 (s)                          Li 35s (5s), ctrl 55s (2s)                                                +++
                                     Time in target section (%)                        Li 7.4% (2.25%), ctrl 1.25% (1.25%)                                       ++
                                     Inhibitory avoidance test (s)                     Li 27 (3), ctrl 9.5 (2)                                                   +++
                                                                                       Late stage disease (7 months)                                             
                                     Escape latency day 4 (s)                          Li 50 (2), ctrl 59 (1)                                                    NR
                                     Time in target section (%)                        Li 1.5 (0.5), ctrl 1.5 (0.5)                                              ±
                                     Inhibitory avoidance test                         Li 14 (3.5), ctrl 8 (4)                                                   ±
  a   Toledo and Inestrosa, [@B55]   **Morris water maze:**                                                                                                      
                                     Escape latency day 5 (s)                          Tg Li−45 (9), ctrl−35 (7.5)                                               ±
                                                                                       WT ctrl−27 (10)                                                           
                                     **Memory flexibility test:**                                                                                                
                                     No. of trials to criterion (\#)                   Tg Li−7 (0.5), ctrl 12 (0.25)                                             \+
                                                                                       WT ctrl−5 (0.25)                                                          
  a   Sy et al., [@B53]              **Morris water maze:**                                                                                                      
                                     Escape latency during day 7 (s)                   Li + Na−25 (2), ctrl + Na−17 (5)                                          NR
                                                                                       Li + LPS−26 (3), ctrl + LPS−20 (3)                                        NR
                                     **Probe trial (24 h)**                                                                                                      
                                     Time spent in target quadrant (s)                 Li + Na−17.5 (4.5), ctrl + Na−22 (4)                                      ±
                                                                                       Li + LPS−19 (2), ctrl + LPS−13 (4)                                        ±
                                     Latency to platform (s)                           Li + Na−24 (6), ctrl + Na−17.5 (5)                                        ±
                                                                                       Li + LPS−26 (5), ctrl + LPS−47.5 (7.5)                                    \+
                                     Number of platform location crosses (\#)          Li + Na−5 (1.3), ctrl + Na−5.4 (1)                                        ±
                                                                                       Li + LPS−3 (0.25), ctrl + LPS−1 (0.5)                                     \+
  a   Nunes et al., [@B40]           **Barnes maze:**                                  Treated before deficits                                                   
                                     Escape latency (s; mean)                          Li−40 (3), ctrl−75 (7)                                                    \+
                                     Time in target quadrant (%)                       Li−52.3 (6.8) Ctrl−22.8 (4.9)                                             +++
                                     Aversive memory test session (s)                  Li−299 (298/300), Ctrl−216 (137/298)                                      ++
                                     **Barnes maze:**                                  Treated after deficits                                                    
                                     Escape latency (s; mean)                          Li -- 25 (2), Ctrl -- 75 (7)                                              \+
                                     Time in target quadrant (%)                       Li−32 (4) Ctrl−22.8 (4.9)                                                 ++
                                     Aversive memory test session (s):                 Li−298 (139/298), Ctrl−216 (137/298)                                      \+
  a   Wilson et al., [@B62]          **Novel object recognition (preference ratio)**   WT Li−0.39 (0.04), veh−0.43 (0.04) Tg AD Li−0.39 (0.02) veh−0.28 (0.02)   NR +
                                     **Morris water maze:**                                                                                                      
                                     Escape latency training day 5 (s)                 WT Li−31 (7), veh−15 (5)                                                  NR
                                                                                       Tg Li−40 (10) AD veh−33 (8)                                               ±
                                     Time in target quadrant (%)                       WT Li−44 (5), veh−48 (5)                                                  ±
                                                                                       Tg AD Li−45 (3), veh−50 (8)                                               ±
                                     **Auditory fear conditioning task:**                                                                                        
                                     Contextual (% freezing)                           WT Li−60 (15), veh−79 (11)                                                ±
                                                                                       Tg AD Li−60 (10) veh−55 (10)                                              ±
                                     Cued recall (% freezing)                          WT Li−55 (15), veh−85 (10)                                                NR
                                                                                       Tg AD Li−63 (7), veh−30 (5)                                               \+
  a   Nery et al., [@B37]            **Avoidance behavior**                                                                                                      
                                     \% animals in non-stimulus area                   Aβ inj Li 65 (2), ctrl: 55 (1)                                            +++
  a   McBride et al., [@B32]         *Treated before deficits*                         Alzheimer\'s Tg:                                                          
                                     **Learning during training (%)**                                                                                            
                                     psn\[B3\]/+ flies                                 Li 75(5) -\> 45(10), ctrl 62.5(7.5) -\> 51 (9)                            +++
                                     psn\[I2\]/+ flies                                 Li 65(7.5) -\> 30(10) ctrl 63(8) -\> 52(8)                                +++
                                     **Short term memory (%)**                                                                                                   
                                     psn\[B3\]/+ flies                                 Li--Naive 90(2), trained 70(5)                                            ++
                                                                                       Ctrl--Naive 76(6), trained 75(6)                                          ±
                                     psn\[I2\]/+ flies                                 Li--Naive 88(2), trained 72(5)                                            \+
                                                                                       Ctrl--Naive 83(5), trained 85 (3)                                         ±
                                     *Treated after deficits*                                                                                                    
                                     **Learning during training (%)**                                                                                            
                                     psn\[B3\]/+ flies                                 Li 65(7.5) -\> 18(7), ctrl 70(5) -\> 62.5(7.5)                            +++
                                     psn\[I2\]/+ flies                                 Li 76(5) -\> 18(7), ctrl 47.5(7.5) -\> 35(7.5)                            +++
                                     **Short term memory (%)**                                                                                                   
                                     psn\[B3\]/+ flies                                 Li--Naive 90(4), trained 62.5(7.5)                                        ++
                                                                                       Ctrl--Naive 70(8), trained 75(7)                                          ±
                                     psn\[I2\]/+ flies                                 Li--Naive 84(6), trained 62.5(7.5)                                        ++
                                                                                       Ctrl--Naive 57.5(7.5), trained 63(8)                                      ±
                                     *Treated before deficits*                                                                                                   
                                     **Short term memory**                             Parkinson\'s Tg:                                                          
                                                                                       Li 80(4) -\> 75(5), ctrl 82.5(5) -\> 78(4)                                ±
  b   Spilman et al., [@B50]         **Morris water maze:**                                                                                                      
                                     Escape latency day 4 (s)                          Tg Rapa 32(3), ctrl 42(5)                                                 \+
                                                                                       WT Rapa 15(2.5), ctrl 32.5(3)                                             NR
                                     Platform crosses (\#)                             Tg Rapa 2.5(0.5), ctrl 0.9(0.1)                                           +/±
                                                                                       WT Rapa 5(1), ctrl 3.1(0.4)                                               NR
  b   Majumder et al., [@B31]        **Morris water maze:**                                                                                                      
                                     Escape latency day 5 (s)                          Pre-AD--Rapa 26.9(2.1), ctrl 37.96(2.9)                                   \+
                                                                                       Est AD -- Rapa 36(2), ctrl 37.96(2.9)                                     ±
                                                                                       YA--Rapa 20.7(1.05), ctrl 29.1(2.7)                                       \+
                                                                                       MA--Rapa 32.5(1.5), ctrl 29.1(2.7)                                        ±
                                     Trial time in target quadrant (s)                 Pre-AD--Rapa 22.5(2.5), ctrl 15(2.5)                                      \+
                                                                                       Est AD--Rapa 17.5(1.5), ctrl 15(2.5)                                      ±
                                                                                       YA--Rapa 29(2), ctrl 21.5(1.5)                                            \+
                                                                                       MA--Rapa 21(1.5), ctrl 21.5(1.5)                                          ±
                                     MWM platform crosses (\#)                         Pre-AD--Rapa 3.5(0.5), ctrl 1.95(0.25)                                    \+
                                                                                       Est AD--Rapa 1.75(0.2), ctrl 1.95(0.25)                                   ±
                                                                                       YA--Rapa 5.25(0.3), ctrl 3.8 (0.25)                                       \+
                                                                                       MA--Rapa 3.5 (0.2), ctrl 3.8 (0.25)                                       ±
                                     Novel object recognition                          Pre-AD--Rapa 65 (7), ctrl 50 (5)                                          \+
                                                                                       Est AD--Rapa 55 (2.5), ctrl 50 (5)                                        ±
                                                                                       YA--Rapa 67.5(2.5), ctrl 70 (4)                                           ±
                                                                                       MA--Rapa 60 (5), ctrl 70 (4)                                              ±
  b   Halloran et al., [@B13]        **Passive avoidance test (s)**                    MA--Rapa 200(40), ctrl 160(40)                                            ±
                                                                                       OA--Rapa 200(30), ctrl 100(20)                                            \+
  b   Majumder et al., [@B30]        **Morris water maze:**                                                                                                      
                                     Escape latency day 5 (s)                          YA--Rapa 21(1), ctrl 30(2.5)                                              \+
                                                                                       MA--Rapa 31(2), ctrl 30(2.5)                                              ±
                                     Time in target quadrant (s)                       YA--Rapa 28.73(1.65), ctrl 21.3(1.24)                                     ++
                                                                                       MA--Rapa 20.97(1.18), ctrl 21.3(1.24)                                     ±
                                     Latency to platform (s)                           YA--Rapa 20(2), ctrl 27(3)                                                \+
                                                                                       MA--Rapa 31(3), ctrl 27(3)                                                ±
                                     Platform crosses                                  YA--Rapa 5.3(0.2), ctrl 3.9(0.15)                                         +++
                                                                                       MA--Rapa 3.5(0.25), ctrl 3.9 (0.15)                                       ±
  b   Lin et al., [@B26]             **Morris water maze:**                                                                                                      
                                     Escape latency day 5 training (s)                 WT--rapa 28(4), ctrl 25(3)                                                
                                                                                       AD--rapa 35(9), ctrl 40(4)                                                ±
                                     Platform crosses (\#)                             WT rapa−3.1(0.5), ctrl 3.9(0.6)                                           
                                                                                       AD rapa−2.1 (0.5), ctrl−0.75 (0.25)                                       \+
  b   Neff et al., [@B35]            **Object place recognition (s)**                  YA rapa--novel 22(3), known 12(2)                                         ±
                                                                                       YA veh--novel 24(4), known 14(2)                                          
                                                                                       MA rapa--novel 15(3), known 10(2)                                         ±
                                                                                       MA veh--novel 17(2), known 15(4)                                          
                                     **Morris water maze:**                                                                                                      
                                     Escape latency day 5 (s)                          YA rapa 30(1), veh 41 (2)                                                 +/±
                                                                                       MA rapa 37 (3), veh 39 (1)                                                +/±
                                     Time in target quadrant (s)                       YA rapa 25(2), veh 21 (2)                                                 ++
                                                                                       MA rapa 25 (2), veh 20 (3)                                                ++
                                     Target crossings (\#)                             YA rapa 2.3(0.2), veh 1.3(0.2)                                            ++
                                                                                       MA rapa 1.5 (0.3), veh 1.5 (0.2)                                          ±
                                     **Context fear conditioning:**                                                                                              
                                     Activity suppression (ratio)                      YA rapa 0.2 (0.02), veh 0.21 (0.02)                                       ++
                                                                                       MA rapa 0.195 (0.01), veh 0.28 (0.02)                                     ++
                                                                                       OA rapa 0.195 (0.01), veh 0.25 (0.04)                                     ++
  b   Wang et al., [@B58]            **Morris water maze:**                                                                                                      
                                     Escape latency day 4 (s)                          Rapa 25(3), ctrl 35(4)                                                    \+
                                     Escape latency trial (s)                          Rapa 16(5), ctrl 32(2.5)                                                  ++
                                     Time in target quadrant (s)                       Rapa 26(3.5), ctrl 12.5(1)                                                ++
  b   Zhu et al., [@B66]             **Morris water maze:**                                                                                                      
                                     Escape latency (s)                                Scop + rapa−50 (7.5)                                                      −
                                                                                       Scop + saline−38 (5)                                                      ++
                                                                                       Saline only−55 (7)                                                        
                                                                                       Scop + rapa + MAD−39 (4)                                                  \+
                                     Time in target quadrant (%)                       Scop + rapa−65 (7)                                                        −
                                                                                       Scop + saline−80 (8)                                                      \+
                                                                                       Saline only−62 (6)                                                        
                                                                                       Scop + rapa + MAD−75 (7.5)                                                \+
  b   Lin et al., [@B25]             **Morris water maze:**                                                                                                      
                                     Escape latency (s)                                Rapa 25(1), ctrl 19(2)                                                    ±
                                     Platform crosses (\#)                             Rapa 1.6(0.25), ctrl 1.75(0.25)                                           ±
  b   Wang et al., [@B59]            **Y-maze (alternation %):**                                                                                                 
                                     4wks post infusion                                Rapa 39(6), ctrl 62(10)                                                   −
                                     8 wks post infusion                               Rapa 48(7), ctrl 53(8)                                                    ±
  b   Jahrling et al., [@B21]        **Morris water maze:**                                                                                                      
                                     Escape latency day 4 (s)                          Rapa 30(4), ctrl 40(5)                                                    +++
                                     Trial time in target quadrant (%)                 Rapa 32(6), ctrl 13(2)                                                    \+
                                     Spatial Novelty (\>0.33 = intact)                 Rapa 0.44 (0.02), ctrl 0.34 (0.02)                                        +++
  b   Zhang et al., [@B65]           **Morris water maze:**                                                                                                      
                                     Escape latency day 5 (s)                          Rapa−32.5(5), veh 67(13)                                                  +++
                                     Time in target quadrant (%)                       Rapa−42.5(7.5), veh 22.5(7.5)                                             \+
                                     Number of platform crossings (\#)                 Rapa−3.75 (5.5), veh−1.5 (0.5)                                            \+
  c   Umeda et al., [@B56]           **Morris water maze:**                                                                                                      
                                     Escape latency day 5 (s)                          12m APP rif−19(5), veh−35(6)                                              ++
                                                                                       18m APP veh−36(5)                                                         
                                                                                       18m APP rif0.5mg−29(5)                                                    ±
                                                                                       18m APP rif1mg−17.5(5)                                                    ++
                                                                                       8m Tau609 rif0.5mg 14(2.3), veh−41(8)                                     \+
                                                                                       15m Tau609 rif1mg 29(7), veh 43(7)                                        ±
                                     Time in target quadrant (%)                       12m APP rif−45(5), veh−29(3)                                              ±
                                                                                       18m APP veh−29(6)                                                         
                                                                                       18m APP rif0.5mg−37(6)                                                    ±
                                                                                       18m APP rif1mg−49(4)                                                      \+
                                                                                       8m Tau609 rif0.5mg 30(4), veh−16(7)                                       \+
                                                                                       15m Tau609 rif0.5mg 42(10), veh−21(9)                                     ±
  d   Lonskaya et al., [@B27]        **Morris water maze:**                                                                                                      
                                     Time in target quadrant (%)                       Aβ icv bosu 29(1), ctrl 19 (1)                                            \+
                                     Time in target quadrant (% of WT)                 Tg bosu 87.5(15) ctrl 75(10)                                              \+
                                     Platform crosses (\#)                             Aβ icv bosu 5.5 (0.5), ctrl 4 (0.25)                                      \+
                                     Platform crosses (% WT)                           Tg bosu 147.5(7.5), ctrl 80(5)                                            \+

*+++ favoring intervention, highly significant p \< 0.001. ++ favoring intervention, significant p \< 0.01. + favoring intervention, significant p \< 0.05. +/± trend favoring intervention, p \< 0.1. ± not significant. +/± trend favoring control, p \< 0.1. --favoring control, significant p \< 0.05. -- favoring control, significant p \< 0.01. --- favoring control, highly significant p \< 0.001. LPS, lipopolysaccharide; MA, treated from middle age; MAD, 3-methyladenine; NR, p-value not reported; OA, treated from old age; Scop, scopolamine; YA, treated from young adulthood*.

###### 

Results of human studies testing the effect of lithium (a), rapamycin (b), rifampicin & doxycycline (c) and nilotinib (d) on cognition.

      **Author, year**           **Cognitive tests**                      **Outcome**                                                                                                                               **Significance**
  --- -------------------------- ---------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------- ------------------
  a   Pomara et al., [@B44]      Buschke selective reminding test         \[2pt\]No quantitative data reported---"None of the psychometric measures showed either consistent, significant increases or decreases"   ±
                                 Digit span/supraspan test                                                                                                                                                          
                                 Sperling test of iconic memory                                                                                                                                                     
                                 Word fluency tasks                                                                                                                                                                 
                                 Wechsler Memory Scale                                                                                                                                                              
  a   Macdonald et al., [@B29]   Change in MMSE                           Li−4.8 (5.5), ctrl−4.0 (5.0)                                                                                                              ±
                                                                                                                                                                                                                    
  a   Hampel et al., [@B14]      MMSE                                     Li−23.6 (1.6) -\> 22.6 (3.5)                                                                                                              ±
                                                                          PBO−23.6 (1.7) -\> 23.2 (2.7)                                                                                                             
                                 ADAS-Cog                                 Li−15.8 (4.2) -\> 15.6 (4.4)                                                                                                              ±
                                                                          PBO−5.4 (5)-\> 16.6 (5.1)                                                                                                                 
                                 ADAS-Cog % with improvement \>4 points   Li−28.6%, PBO−14.3%                                                                                                                       NR
                                                                                                                                                                                                                    
  a   Leyhe et al., [@B24]       ADAS-Cog                                 Li 19.2 (5.7) -\> 17.7 (5.8)                                                                                                              \+
                                                                          PBO 16.5 (5.1) -\> 18.0 (5.1)                                                                                                             
  a   Forlenza et al., [@B10]    ADAS-Cog                                 Li 11.0(6.7)-\>12.6(6.6), PBO 10.7(5.1)-\> 13.9(8.5)                                                                                      \+
                                 CDR--SoB                                 Li 1.4(1.3) -\> 2.2(1.8), PBO 1.9(1.4) -\> 2.8(2.3)                                                                                       ±
                                 Delayed recall                           Li 4.8(2.1) -\> 4.8(2.2), PBO 4.2(2.3) -\> 4.5(2.3)                                                                                       ±
                                 Figure recall                            Li 2.3(1.2) -\> 2.0(1.3), PBO 1.9(1.1) -\> 1.6(1.2)                                                                                       ±
                                 Sequence letters & numbers               Li 6.4(2.1) -\> 6.0(2.9), PBO 6.3(2.6) -\> 5.1(2.6)                                                                                       \+
                                 Trail making test A (s)                  Li 69.1(44.2) -\> 62.8(31.5), PBO 89.9(67.4) -\> 63.6(41.9)                                                                               ±
                                 Trail making test B                      Li 171.8(83.9) -\> 184.9(78.1), PBO 207.1 (79.6) -\> 190.7 (92.8)                                                                         ±
                                 Conversion MCI-\>AD                      Li (*n* = 20) Stable = 16, Progress = 4                                                                                                   ±
                                                                          PBO (*n* = 20) Stable = 13, Progress = 7                                                                                                  
                                 MCI-\>AD converters CDR-SoB              Li 3.3(1.3) -\> 4.4(1.5), PBO 3.4(1.4) -\> 5.6(1.5)                                                                                       \+
  a   Nunes et al., [@B41]       MMSE                                     Li 19.48 (0.67) -\> 19.82 (0.9)                                                                                                           +++
                                                                          PBO 17.95 (0.73) -\> 14 (1.326)                                                                                                           
  b   Kraig et al., [@B23]       Pre-post test change                                                                                                                                                               
                                 EXIT25                                   PBO 0.38 (-1.84, 2.61), rapa−0.1 (-3.31, 3.11)                                                                                            ±
                                 SLUMS                                    PBO 0.38 (-2.03, 1.26), rapa−0.8 (-3.92, 2.32)                                                                                            ±
                                 TAPS                                     PBO−1 (-3.18, 1.18), rapa 1.44 (-1.68, 4.57)                                                                                              ±
  c   Molloy et al., [@B34]      SADAS-Cog                                Rif−0m = 22, 12m = 27.5                                                                                                                   ---
                                                                          Doxy -- 0m = 21, 12m = 25.5                                                                                                               ---
                                                                          Rif + Doxy−0m = 22, 12m = 28                                                                                                              ---
                                                                          PBO−0m = 21, 12m = 25                                                                                                                     
                                 CDR-SoB mean                             Rif−0m = 6, 12m = 8.5                                                                                                                     ±
                                                                          Non-Rif−0m = 5.75, 12m = 7.75                                                                                                             
                                                                          Doxy -- 0m = 6, 12m = 8.5                                                                                                                 ±
                                                                          Non-Doxy -- 0m = 5.75, 12m = 7.8                                                                                                          
                                 SMMSE                                    ns vs. placebo, data NR                                                                                                                   ±
                                 Qmci                                     Rif worse than PBO, data NR                                                                                                               ---
  d   Pagan et al., [@B42]       MMSE (change 0w-\>24w)                   150mg--+3.85, 300mg--+3.5                                                                                                                 NR
                                 SCOPA-Cog (change 0w-\>24w)              150mg--+1.85, 300mg--+2.00                                                                                                                

*+++ favoring intervention, highly significant p \< 0.001. ++ favoring intervention, significant p \< 0.01. + favoring intervention, significant p \< 0.05. +/± trend favoring intervention, p \< 0.1. ± not significant. +/± trend favoring control, p \< 0.1. - favoring control, significant p \< 0.05. -- favoring control, significant p \< 0.01. --- favoring control, highly significant p \< 0.001. EXIT25, Executive interview; NR, p-value not reported; PBO, placebo; RoB, Cochrane risk of bias; SLUMS, St Louis University Memory Status; TAPS, Texas Assessment of Processing Speed*.

Rapamycin and cognitive aging
-----------------------------

Rapamycin has been identified as the second most frequently investigated (*n* = 13 studies) proteostasis modulator. Twelve animal studies (10 mice, 2 rats), predominately using an Alzheimer\'s disease model, investigated the influence of rapamycin on cognitive aging (Table [1](#T1){ref-type="table"}). Overall, nine out of twelve animal studies reported a statistically significant benefit on at least one cognitive outcome, irrespective of treatment duration (Table [3](#T3){ref-type="table"}). One human study investigating safety, efficacy and tolerability of rapamycin in humans (Kraig et al., [@B23]), did not report any significant benefit to overall cognition in an older population (Table [4](#T4){ref-type="table"}).

Rifampicin, tetracycline antibiotics, tyrosine kinase inhibitors and cognitive aging
------------------------------------------------------------------------------------

Rifampicin, tetracycline antibiotics and tyrosine kinase inhibitors have been tested in both animal and human models (Tables [1](#T1){ref-type="table"}, [2](#T2){ref-type="table"}). The two rifampicin studies (1 mouse, 1 human; Tables [3](#T3){ref-type="table"}, [4](#T4){ref-type="table"}) investigating its therapeutic effects for Alzheimer disease had opposite findings, with positive cognitive outcomes in mice (Umeda et al., [@B56]), but no benefit found in the human study (Molloy et al., [@B34]).

Studies of tetracycline antibiotics showed similar results to rifampicin, with minocycline showing cognitive benefits in two studies using rat and chicken models of Alzheimer disease (Supplementary Table [1](#SM1){ref-type="supplementary-material"}, Supplementary Table [2](#SM1){ref-type="supplementary-material"}), while another tetracycline, doxycycline, showed no benefit in human AD patients, either alone or in combination with rifampicin (Molloy et al., [@B34]).

The tyrosine kinase inhibitor, bosutinib, was reported in mouse models of Alzheimer\'s disease as statistically beneficial to cognitive function, and another tyrosine kinase inhibitor, nilotinib, was found to improve scores on the MMSE and SCOPA-Cog in an open-label study in patients with Parkinson\'s disease, however the statistical significance was not reported (Tables [3](#T3){ref-type="table"}, [4](#T4){ref-type="table"}).

Other proteostasis-modifying drugs
----------------------------------

There were six proteostasis modulators that have been tested to improve cognitive outcomes in animal models but are yet to be studied in human populations---M-CSF, GM-CSF, methylene blue, GGA, dantrolene, and phenylbutyric acid (Supplementary Table [1](#SM1){ref-type="supplementary-material"}). Both of the M/GM-CSF studies indicated beneficial outcomes with the use of these therapeutics in mouse models of Alzheimer\'s disease, as was the case with methylene blue, GGA and phenylbutyric acid (Supplementary Table [2](#SM1){ref-type="supplementary-material"}). Studies of dantrolene to improve cognitive outcomes showed a statistically significant improvement in one mouse model of Alzheimer\'s (Peng et al., [@B43]) but no benefit to cognition in another (Wu et al., [@B63]), with one study in aged rats indicating a trend toward benefit on Morris water maze performance.

Risk of bias
------------

Table [5](#T5){ref-type="table"} shows the SYRCLE risk of bias ratings for animal studies. The majority of animal studies had an unclear risk of bias, as specific details of randomization and blinding were often not provided. Most studies provided information on the baseline characteristics of animals, and some studies did specify that the investigator performing behavioral assessments of the animals was blinded to the treatment status of the animal, indicating low risk of bias where this was the case. Overall the risk of bias was similar across studies regardless of the drug being tested.

###### 

SYRCLE Risk of Bias for animal studies.

  **Author, year**               **Sequence generation**   **Baseline characteristics**   **Allocation concealment**   **Random Housing**   **Blinding of personnel & participants**   **Random outcome assessment**   **Incomplete outcome data**   **Selective outcome reporting**
  ------------------------------ ------------------------- ------------------------------ ---------------------------- -------------------- ------------------------------------------ ------------------------------- ----------------------------- ---------------------------------
  **LITHIUM**                                                                                                                                                                                                                                        
  Caccamo et al., [@B6]          Unclear                   Low                            Unclear                      Unclear              Unclear                                    Unclear                         Low                           Low
  Nocjar et al., [@B39]          Unclear                   Low                            Unclear                      Unclear              Low                                        Unclear                         Low                           Low
  Rockenstein et al., [@B46]     Unclear                   Unclear                        Unclear                      Unclear              Unclear                                    Unclear                         Low                           Low
  Fiorentini et al., [@B9]       Unclear                   Low                            Unclear                      Unclear              Unclear                                    Unclear                         Low                           Low
  Toledo and Inestrosa, [@B55]   Unclear                   Unclear                        Unclear                      Unclear              Unclear                                    Unclear                         Low                           Low
  Sy et al., [@B53]              Unclear                   Low                            Unclear                      Unclear              Unclear                                    Unclear                         Low                           High
  Nunes et al., [@B40]           Unclear                   Low                            Unclear                      Unclear              Unclear                                    Unclear                         Low                           Low
  Wilson et al., [@B62]          Unclear                   Unclear                        Unclear                      Unclear              Unclear                                    Unclear                         Low                           Low
  Nery et al., [@B37]            Unclear                   Low                            Unclear                      Unclear              Unclear                                    Low                             Low                           Low
  McBride et al., [@B32]         Unclear                   Low                            Unclear                      Unclear              Low                                        Unclear                         Low                           Low
  **RAPAMYCIN**                                                                                                                                                                                                                                      
  Spilman et al., [@B50]         Unclear                   Low                            Unclear                      Unclear              Unclear                                    Unclear                         Low                           Low
  Majumder et al., [@B31]        Unclear                   Unclear                        Unclear                      Unclear              Unclear                                    Unclear                         Low                           Low
  Halloran et al., [@B13]        Unclear                   Unclear                        Unclear                      Unclear              Unclear                                    Unclear                         Low                           Low
  Majumder et al., [@B30]        Unclear                   Unclear                        Unclear                      Unclear              Unclear                                    Unclear                         Low                           Low
  Lin et al., [@B26]             Unclear                   Low                            Unclear                      Unclear              Low                                        Unclear                         Low                           Low
  Neff et al., [@B35]            Unclear                   Low                            Unclear                      Unclear              Low                                        Unclear                         Low                           Low
  Wang et al., [@B58]            Unclear                   Low                            Unclear                      Unclear              Unclear                                    Unclear                         Low                           Low
  Zhu et al., [@B66]             Low                       Low                            Unclear                      Unclear              Unclear                                    Unclear                         Low                           Low
  Lin et al., [@B25]             Unclear                   Low                            Unclear                      Unclear              Low                                        Unclear                         Low                           Low
  Wang et al., [@B59]            Unclear                   Low                            Unclear                      Unclear              Unclear                                    Unclear                         Low                           Low
  Jahrling et al., [@B21]        Unclear                   Low                            Unclear                      Unclear              Low                                        Unclear                         Low                           Low
  Zhang et al., [@B65]           Unclear                   Low                            Unclear                      Unclear              Unclear                                    Unclear                         Low                           Low
  **RIFAMPICIN**                                                                                                                                                                                                                                     
  Umeda et al., [@B56]           Unclear                   Low                            High                         Unclear              High                                       Unclear                         Low                           Low
  **BOSUTINIB**                                                                                                                                                                                                                                      
  Lonskaya et al., [@B27]        Unclear                   Low                            Unclear                      Unclear              Low                                        Unclear                         Low                           High
  **M-CSF**                                                                                                                                                                                                                                          
  Boissonneault et al., [@B3]    Unclear                   Low                            Unclear                      Unclear              Low                                        Unclear                         High                          High
  **GM-CSF**                                                                                                                                                                                                                                         
  Boyd et al., [@B5]             Unclear                   Unclear                        Unclear                      Unclear              Unclear                                    Unclear                         Low                           High
  **METHYLENE bLUE**                                                                                                                                                                                                                                 
  Deiana et al., [@B8]           Low                       Unclear                        Unclear                      Unclear              Unclear                                    Unclear                         Low                           Low
  Hochgräfe et al., [@B16]       Unclear                   Low                            Unclear                      Unclear              Unclear                                    Unclear                         Low                           Low
  Medina et al., [@B33]          Unclear                   Low                            Unclear                      Unclear              Unclear                                    Unclear                         Low                           High
  Stack et al., [@B51]           Low                       Low                            Unclear                      Unclear              Unclear                                    Unclear                         Low                           Low
  **GGA**                                                                                                                                                                                                                                            
  Hoshino et al., [@B19]         Unclear                   Unclear                        Unclear                      Unclear              Unclear                                    Unclear                         Low                           Low
  Sun et al., [@B52]             Unclear                   Unclear                        Unclear                      Unclear              Unclear                                    Unclear                         Low                           Low
  **DANTROLENE**                                                                                                                                                                                                                                     
  Hopp et al., [@B18]            Unclear                   Low                            Unclear                      Unclear              Unclear                                    Unclear                         Low                           Low
  Peng et al., [@B43]            Unclear                   Low                            Unclear                      Unclear              Unclear                                    Unclear                         Low                           Low
  Wu et al., [@B63]              Unclear                   Low                            Unclear                      Unclear              Unclear                                    Unclear                         Low                           Low
  **PHENYLBUTYRIC ACID**                                                                                                                                                                                                                             
  Wiley et al., [@B61]           Unclear                   Low                            Unclear                      Unclear              Low                                        Unclear                         Low                           Low
  **MINOCYCLINE**                                                                                                                                                                                                                                    
  Choi et al., [@B7]             Unclear                   Low                            Unclear                      Unclear              Unclear                                    Unclear                         Low                           High
  Gibbs and Gibbs, [@B12]        Unclear                   Low                            Unclear                      Unclear              Unclear                                    Unclear                         Low                           Low

Table [6](#T6){ref-type="table"} shows the Cochrane risk of bias rating for human studies. There was significant heterogeneity among lithium studies, with (Pomara et al., [@B44]; Macdonald et al., [@B29]) scoring high risk of bias across most or all domains due to an open label design and not reporting all quantitative outcome data. (Hampel et al., [@B14]) had an intermediate risk of bias as investigators were aware of patient treatment status. Studies by Leyhe et al. ([@B24]), Forlenza et al. ([@B10]) and Nunes et al. ([@B41]) scored a lower risk of bias due to randomized, double-blind designs, though details of sequence generation and allocation concealment were not reported. Studies of rapamycin (Kraig et al., [@B23]) and rifampicin (Molloy et al., [@B34]) scored a low risk of bias across most domains. The study using nilotinib (Pagan et al., [@B42]) was rated as having a high risk of bias across most domains, due to an open label design.

###### 

Cochrane Risk of Bias for human studies.

  **Author, year**           **Sequence generation**   **Allocation concealment**   **Blinding of personnel & participants**   **Blinding of outcome assessment**   **Incomplete outcome data**   **Selective outcome reporting**
  -------------------------- ------------------------- ---------------------------- ------------------------------------------ ------------------------------------ ----------------------------- ---------------------------------
  **LITHIUM**                                                                                                                                                                                     
  Pomara et al., [@B44]      High                      High                         High                                       High                                 High                          Unclear
  Macdonald et al., [@B29]   High                      High                         High                                       High                                 High                          High
  Hampel et al., [@B14]      Low                       Unclear                      Low                                        High                                 Low                           Low
  Leyhe et al., [@B24]       Unclear                   Unclear                      Low                                        Unclear                              Low                           Low
  Forlenza et al., [@B10]    Unclear                   Unclear                      Low                                        Low                                  Low                           Low
  Nunes et al., [@B41]       Unclear                   Unclear                      Low                                        Low                                  Low                           Low
  **RAPAMYCIN**                                                                                                                                                                                   
  Kraig et al., [@B23]       Low                       Unclear                      Low                                        Low                                  Low                           Low
  **RIFAMPICIN**                                                                                                                                                                                  
  Molloy et al., [@B34]      Low                       Low                          Low                                        Low                                  Low                           Low
  **NILOTINIB**                                                                                                                                                                                   
  Pagan et al., [@B42]       High                      High                         High                                       High                                 Low                           Low

Registered human trials
-----------------------

Figure [2](#F2){ref-type="fig"} shows the progress of the drugs identified in our search from animal into human studies, including planned or ongoing studies registered on clinicaltrials.gov. Nilotinib has two phase 2 studies registered, one in Alzheimer\'s disease and one in Parkinson\'s disease. Lithium has one phase 4 study registered, while GM-CSF and phenylbutyric acid each have one phase 2 study registered in Alzheimer\'s disease.

Discussion {#s4}
==========

In this review we have summarized all current animal and human research studies that have investigated the effect of proteostasis modulators on cognitive function. Overall, the therapeutic alteration of proteostasis pathways using repurposed drugs is a promising approach to the treatment of dementia and age-related cognitive decline with a reasonable research translation between animal and human studies showing similar conclusions observed across the studies.

Lithium
-------

Lithium was the most studied proteostasis modifying drug identified in this review, and the furthest progressed in translation to treatment of age-related dementia. All except one of the animal studies included in this review showed a benefit to at least one cognitive outcome despite heterogeneity in species, model, dose, stage of disease at intervention and duration of treatment. Three of six human studies also found benefit, and consistent with the results in mice the largest effect was observed with microdoses and long duration of treatment (Nunes et al., [@B41]). The only negative RCT used a high dose for a short duration (Hampel et al., [@B14]). Taken together, these studies show lithium has a consistent benefit in Alzheimer\'s disease in animal models and humans, which appears more pronounced with lower doses, longer durations of treatment, and when commenced at an earlier stage of disease.

The apparent superiority of lower doses of lithium is encouraging, as at standard psychiatric dose it can have renal and thyroid-related side effects that limit tolerability and is toxic at levels only slightly above the therapeutic range (Timmer and Sands, [@B54]). Higher lifetime exposure to natural microlevels of lithium in drinking water is associated with a reduced incidence of dementia (Kessing et al., [@B22]), a finding which adds plausibility to the idea that microdoses of lithium rather than the current therapeutic doses might be beneficial for the treatment of dementia.

A possible explanation for lithium\'s non-linear dose response involves the interaction between lithium\'s autophagy-enhancing inhibition of inositol triphosphate receptor (IP3R) signaling, and its autophagy-reducing inhibition of GSK-3B, a tau-phosphorylating kinase (Sarkar et al., [@B48]). Genetic reduction of IP3R signaling in drosophila rescues Alzheimer\'s disease phenotypes in the same way lithium does (McBride et al., [@B32]), suggesting lithium\'s inhibition of IP3R signaling via reducing the formation of inositol triphosphate (IP3) may be sufficient to cause its benefits. This is mechanistically plausible, as inhibition of IP3R signaling enhances autophagy through decreasing calcium release from the endoplasmic reticulum, enhancing proteostasis (Sarkar et al., [@B47]). However; lithium\'s inhibition of GSK3B has also been postulated to have beneficial effects in Alzheimer\'s disease via reducing tau phosphorylation and neurofibrillary tangle formation as well as inhibiting autophagy via increasing mTOR signaling (Sarkar et al., [@B48]). Although, this latter theory is less likely to explain the positive influence of microdoses of lithium as lower levels of lithium do not inhibit GSK-3B in mice (Nunes et al., [@B40]). However, this GSK-3B mechanism may explain the reduced efficacy of lithium observed with increasing doses. Increased mTOR signaling due to GSK3B inhibition counteracts the autophagy-enhancing effects of reduced IP3R activation beyond a certain dose (Sarkar et al., [@B49]). If increased mTOR activity limits the effective dose of lithium, this raises the question of whether an mTOR inhibitor such as rapamycin combined with lithium would have beneficial synergistic effects in dementia or cognitive aging. A synergistic benefit of lithium and rapamycin has been demonstrated in a drosophila Huntington\'s disease model (Sarkar et al., [@B48]), but to our knowledge this has not been explored in models of Alzheimer\'s disease.

Rapamycin
---------

Predictably, rapamycin the known inhibitor of mTOR was also one of the most studied proteostasis modulators investigated, more so in animal models then in humans. Overall, the trials indicated a positive therapeutic effect of rapamycin on cognitive outcomes. Cognitive benefits via rapamycin was demonstrated in models of normal aging (Majumder et al., [@B31], [@B30]; Neff et al., [@B35]; Wang et al., [@B58]), vascular dementia (Jahrling et al., [@B21]), and transgenic Alzheimer\'s disease models (Spilman et al., [@B50]; Majumder et al., [@B31]; Lin et al., [@B26]; Zhang et al., [@B65]), which suggests rapamycin has potential to rescue cognitive decline caused by a range of pathologies. This breadth of efficacy is a promising characteristic, as autopsy studies have demonstrated that mixed pathology is common in dementia sufferers (Nelson et al., [@B36]).

Majumder et al. ([@B31]) reported a possible mechanism explaining their findings that rapamycin while effective in preventing cognitive decline before pathology develops, fails as a treatment once Alzheimer\'s pathology is established. They found rapamycin induces autophagy strongly both before and after Alzheimer\'s pathology is present. However, increased autophagy induction fails to reduce levels of amyloidβ in mice with established disease and leads to accumulation of enlarged autophagosomes containing undigested material. This finding suggests deficient substrate clearance and is consistent with previous findings that autophagy in Alzheimer\'s disease is principally defective at the stage of autolysosomal proteolysis (Nixon and Yang, [@B38]; Bordi et al., [@B4]). Therefore, to be effective in established Alzheimer\'s dementia rapamycin may need to be combined with a drug that can enhance autophagy at the stage of autolysosomal digestion.

Rapamycin\'s demonstrated ability to improve phenotypes of aging in animals has recently led to human trials assessing safety and efficacy in older adults (Kraig et al., [@B23]). Despite demonstrating low-dose rapamycin can be used safely in older adults, they were unable to show significant enhancement of cognition. However, larger trials are required to determine the potential benefit of rapamycin\'s for cognitive aging in humans.

Rifampicin, tetracycline antibiotics and tyrosine kinase inhibitors
-------------------------------------------------------------------

Rifampicin was more effective when started earlier in the disease process, and when used at a higher dose (Umeda et al., [@B56]). Cohorts treated with the lower dose at a later stage of disease did not show an improved cognitive benefit, a finding which is relevant to interpreting the DARAD study of rifampicin in Alzheimer\'s disease by Molloy et al. ([@B34]).

In the DARAD study, rifampicin was tested in Alzheimer\'s patients at a low dose and showed either no benefit or on some measures a significant worsening of cognition compared to placebo. A possible explanation for this failure is an insufficient dose and treatment duration. Data supporting this view is provided by Iizuka et al. ([@B20]), who in an observational study determined that a minimum dose rifampicin of 450 mg/day for at least 12 months was required before any cognitive improvement was observed (Iizuka et al., [@B20]).

Doxycycline also failed to produce benefit for human Alzheimer\'s disease patients in the DARAD study (Molloy et al., [@B34]), despite positive animal studies with closely related tetracycline antibiotic minocycline (Choi et al., [@B7]; Gibbs and Gibbs, [@B12]). It is difficult to know what implications this has for minocycline\'s repurposing potential, however currently there are no upcoming human studies registered on clinicaltrials.gov for either doxycycline or minocycline in dementia.

Lonskaya et al examined bosutinib in two mouse models of established Alzheimer\'s disease, and demonstrated statistically significant benefits after 3 weeks of treatment. Beneficial effects on cognition were also observed in human Parkinson\'s disease patients by Pagan et al. although the small size and open label design of the study mean the results require confirmation in larger randomized trials. These promising findings have led to significant interest in repurposing these drugs, to the extent phase 2 clinical trials are currently assessing the effect of these drugs in Alzheimer\'s and Parkinson\'s disease cohorts.

Other proteostasis-modifying drugs
----------------------------------

Three other proteostasis-modifying drugs have excited interest in translating promising animal study findings into humans---GM-CSF, methylene blue and phenylbutyric acid have registered phase 2 studies on clinicaltrials.gov to test their use in Alzheimer\'s disease.

Dantrolene is a drug of interest due to similarities it shares with lithium, in that it enhances autophagy by reducing calcium efflux from the endoplasmic reticulum (Wang et al., [@B60]). Unlike lithium however it acts by inhibition of the ryanodine receptor rather than IP3R signaling, raising the possibility of a complementary mechanism of action (Vervliet et al., [@B57]). This suggests dantrolene is worth testing in human trials to determine whether it can provide similar benefits to lithium, and in combination with lithium in animal models for potential synergistic effects. Currently however, no human trials are registered on clinicaltrials.gov for dantrolene in dementia.

Limitations {#s5}
===========

Our study has several limitations. Our search strategy was based primarily on key terms related to the mechanisms of proteostasis, with the addition of a selection of drugs well known to modulate these processes. Therefore, our search may have missed studies that examine proteostasis-modifying drugs not named in our search and not mentioning proteostasis related key terms. However, we addressed this by adding relevant articles by snowballing.

Secondly, because the present study\'s focus is restricted to approved drugs, it does not provide an adequate overview of the translational pipeline where a repurposed drug is used as the basis for novel molecules that proceed into later stage studies.

Third, we cannot exclude publication bias, particularly in animal studies which are unlikely to be registered beforehand and may be less likely to be published if results are negative.

Conclusions {#s6}
===========

The results of this review support the concept of a translational approach to repurposing proteostasis modifying drugs for the treatment of age-related dementia and cognitive decline. However, larger clinical trials assessing the influence of these drugs particularly, lithium and rapamycin are required before they are ready for the clinic. In addition, animal models assessing whether the combination of proteostasis modulators can act in synergy to improve cognitive outcomes are required. A translational strategy based on systematic screening of rational drug combinations starting in simple model organisms such as C. elegans may provide a pipeline of novel candidate therapies to advance into human studies.
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